May 04, 2020

Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates

Top line results from pivotal Phase 3 trial with roluperidone in negative symptoms in patients diagnosed with schizophrenia on track for release in second quarter

WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2020.

“We are pleased to report that we are approaching the conclusion of the double-blind, 12-week phase of our pivotal Phase 3 trial with roluperidone and reiterate our previous guidance that we expect to report top line results in the second quarter,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Progress in this trial has been unaffected to date by the coronavirus pandemic and we are continually monitoring each trial site and our contract research organizations to ensure the safety of all patients and their access to study drug,” said Dr. Luthringer.  “The last patient visit has taken place in the double-blind phase of the trial, in which a total of 515 patients were enrolled.  In total, 362 patients have completed the double-blind phase, 333 patients from the double-blind phase have elected to transition into the open-label extension period, and 92 patients have completed the extension phase as of April 30, 2020.

“Finally, the prominent role of negative symptoms in schizophrenia has been increasingly highlighted by the key opinion leader (KOL) community since we initiated the Phase 3 trial,” said Dr. Luthringer.  “Our recent KOL webcast, which included the participation of Dr. Stephen Marder, Dr. William Carpenter, Dr. Ofer Agid and Dr. John Kane, discussed how roluperidone may play an important role in treating the negative symptoms of schizophrenia, which persist and worsen over the lifetimes of the majority of patients, accounting for their functional disability and severely limiting their social and vocational reintegration over the long term.” 

Clinical Development Updates

Roluperidone (MIN-101):

Following the completion of enrollment in a pivotal Phase 3 trial with roluperidone ( identifier: NCT033971340) to treat negative symptoms in schizophrenia in February 2020, top-line results from this trial are expected in the second quarter of 2020, consistent with previous guidance.  In parallel with completing this trial, the Company is advancing preparatory work for regulatory filing and commercialization, including clinical pharmacology studies, manufacturing of registration batches of the drug, medical affairs, commercialization strategy and product launch planning.

Seltorexant (MIN-202)

The Company and its co-development and co-commercialization partner, Janssen Pharmaceutica NV, met recently with the U.S. Food and Drug Administration (FDA) to discuss the Phase 3 program for seltorexant based on findings from trials with seltorexant completed in 2019.  The two companies are consulting with each other and with the FDA and the European Medicines Agency/ Committee for Medicinal Products for Human Use about a target indication of adjunctive Major Depressive Disorder (aMDD) in patients with insomnia symptoms and clinical trials to support that target indication.

First Quarter 2020 Financial Results

  • Net Loss:  Net loss was $12.2 million for the first quarter of 2020, or a loss per share of $0.31 (basic and diluted), compared to a net loss of $15.8 million for the first quarter of 2019, or a loss per share of $0.41 (basic and diluted).
  • R&D Expenses: Research and development (R&D) expenses were $8.1 million in the first quarter of 2020, compared to $11.6 million in the first quarter of 2019.  The decrease in R&D expenses primarily reflects lower development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. R&D expenses are expected to decrease during 2020 with the completion of the Phase 2b trial of MIN-117 and the 12-week, double-blind portion of the Phase 3 clinical trial of roluperidone.
  • G&A Expenses: General and administrative (G&A) expenses were $4.2 million in the first quarter of 2020, compared to $4.7 million in the first quarter of 2019. This decrease in G&A expenses was primarily due to a decrease in non-cash stock-based compensation expenses and a decrease in professional fees.
  • Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2020 were approximately $37.6 million

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 3969525.

The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit  

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone (MIN-101) and seltorexant (MIN-202); the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; management’s ability to successfully achieve its goals; and the impact of the coronavirus (COVID-19) pandemic.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 4, 2020.  Copies of reports filed with the SEC are posted on our website at The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

  March 31, December 31,
    2020     2019  
  (in thousands)
Current Assets:    
Cash and cash equivalents $ 30,036   $ 21,413  
Marketable securities   7,478     24,442  
Restricted cash   100     100  
Prepaid expenses and other current assets   852     1,182  
Total current assets   38,466     47,137  
Equipment, net   12     16  
Other noncurrent assets   15     15  
Operating lease right-of-use assets   224     262  
In-process research and development   15,200     15,200  
Goodwill   14,869     14,869  
Total Assets $ 68,786   $ 77,499  
Current Liabilities:    
Accounts payable $ 3,003   $ 2,317  
Accrued expenses and other current liabilities   3,936     4,139  
Operating leases   179     173  
Total current liabilities   7,118     6,629  
Long-Term Liabilities:    
Deferred taxes   1,803     1,803  
Deferred revenue   41,176     41,176  
Noncurrent operating leases   64     111  
Total liabilities   50,161     49,719  
Stockholders' Equity:    
Common stock   4     4  
Additional paid-in capital   317,508     314,512  
Accumulated deficit   (298,887 )   (286,736 )
Total stockholders' equity   18,625     27,780  
Total Liabilities and Stockholders' Equity $ 68,786   $ 77,499  

    Three Months Ended March 31,
    (in thousands, except per share amounts)
      2020     2019  
Revenues   $ -   $ -  
Operating expenses:      
Research and development     8,083     11,606  
General and administrative     4,189     4,706  
Total operating expenses     12,272     16,312  
Foreign exchange losses     (9 )   (6 )
Investment income     130     491  
Net (loss) income   $ (12,151 ) $ (15,827 )
Loss per share:      
Basic and diluted   $ (0.31 ) $ (0.41 )
Weighted average shares:      
Basic and diluted     39,178     38,968  

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Minerva logo

Source: Minerva Neurosciences, Inc